An old arthritis drug restored broken mitochondria in kidney cancer — in lab models

Clear cell renal cell carcinoma — the most common adult kidney cancer — often carries a silenced chromatin-remodeling machine, but nobody knew exactly how that architectural defect made tumors aggressive. A new study in Nature Communications (Un, Hao, Wang, Sun et al., published October 8, 2026), from researchers at Huazhong University of Science and Technology and Tongji Hospital, traces a complete causal chain: losing the chromatin protein SMARCD1 degrades the mitochondrial-fusion protein MFN1, fragments the cell's energy network, and rewires metabolism to feed tumor growth — and the decades-old arthritis drug leflunomide reversed it all in preclinical models.

What does losing SMARCD1 do to a kidney tumor?

The team found SMARCD1 — a core subunit of the SWI/SNF chromatin-remodeling complex, the machinery that controls which genes are accessible for transcription — being progressively switched off in clear cell kidney tumors. The silencing was epigenetic: the DNMT3B enzyme methylated SMARCD1's promoter region, locking the gene shut. With SMARCD1 gone, an RNA helicase called DDX3X gained access to the promoter of MAFF, a small transcription factor. MAFF then promoted the ubiquitin-mediated destruction of MFN1 (mitofusin 1), the GTPase embedded in the outer mitochondrial membrane that is essential for mitochondrial fusion. The result was a fragmented mitochondrial network, a metabolic shift toward oxidative phosphorylation — the oxygen-dependent mode of ATP generation many tumors exploit under stress — and enhanced metastatic potential, linking a nuclear defect directly to cancer's clinical behavior.

Why do fragmented mitochondria matter here?

The mitochondrial mechanism is where this becomes medicine-relevant. Healthy mitochondria continuously fuse and re-fuse, mixing their contents across a tubule network that supports efficient energy production, calcium handling, and quality control. When MFN1 is destroyed, fusion collapses and mitochondria fragment — and that structural breakdown is itself the metabolic reprogramming, not a side effect of it. The SMARCD1-MAFF-MFN1 axis is a direct, causal bridge between chromatin remodeling and mitochondrial dynamics, two hallmarks of cancer that had largely been studied in parallel. Because SWI/SNF complexes are disrupted in roughly one in five human cancers, this template may explain how epigenetic lesions sculpt metabolism in other tumor types too — making mitochondrial fusion a genuinely druggable node downstream of a tumor suppressor loss.

How did an old arthritis drug reverse it?

The therapeutic angle is unusually close to the clinic because leflunomide is already FDA-approved. Best known as a dihydroorotate dehydrogenase inhibitor used in rheumatoid arthritis, the drug restored MFN1 levels and mitochondrial function in SMARCD1-deficient cells and suppressed tumor progression across multiple preclinical models. In patient-derived xenografts — fragments of human tumors grown in mice that retain much of the original cancer's molecular character — leflunomide also potentiated both tyrosine kinase inhibitors and immune checkpoint blockade, the exact two drug classes that form the backbone of advanced kidney cancer therapy, where resistance routinely develops. SMARCD1 promoter methylation could serve as a biomarker to select patients for a precision-medicine trial, consistent with the broader move toward molecularly stratified oncology.

The honest catch — and what comes next

The caveats are standard but important: this is entirely preclinical, spanning cell lines, animal models, and xenografts. No human has received leflunomide for kidney cancer in a trial, so efficacy, oncology-appropriate dosing, and safety in the cancer setting are unknown — and repurposing is a strategy specifically for SMARCD1-deficient disease, not kidney cancer in general. The mitochondrial shift toward oxidative phosphorylation also deserves scrutiny, since some kidney cancers run on glycolysis; tumor heterogeneity will matter. Still, the established human safety profile and generic availability mean the path to a first clinical test could be unusually short. Watch for whether investigators launch a biomarker-selected trial measuring MAFF, MFN1, or mitochondrial morphology in tumor biopsies as readouts.

Where the evidence stands

• Established: Leflunomide is FDA-approved for rheumatoid arthritis and psoriatic arthritis with a long-established human safety profile and generic availability; advanced clear cell renal cell carcinoma is currently managed with VEGF-targeted tyrosine kinase inhibitors and PD-1/PD-L1 checkpoint inhibitors.
• Preliminary: The SMARCD1-MAFF-MFN1 signaling axis, the metabolic shift toward oxidative phosphorylation, and leflunomide's restoration of mitochondrial fusion and tumor suppression were demonstrated in cell lines, animal models, and patient-derived xenografts — not in human clinical trials.
• Absent: Any clinical trial data on leflunomide for kidney cancer — efficacy, oncology-appropriate dosing, safety in the cancer setting, and which molecular subgroups benefit are all untested.